Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Drug Profile

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-FGF23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; burosumab-twza; Crysvita; KRN-23; UX 023

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Kyowa Hakko Kirin; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets; Osteomalacia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed X-linked dominant hypophosphataemic rickets
  • Phase III Osteomalacia
  • Phase II Nevus

Most Recent Events

  • 17 May 2018 Efficacy and adverse events data from the phase III PIXLES trial in X-linked dominant hypophosphataemic rickets released by Ultragenyx Pharmaceutical (NCT02915705)
  • 01 May 2018 Preregistration for X-linked dominant hypophosphataemic rickets (In children, In infants, In adolescents, In adults) in Canada (SC)
  • 27 Apr 2018 Launched for X-linked dominant hypophosphataemic rickets (In children, In infants, In adults) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top